N-cyclohexyl-N-[2-(3,5-difluoroanilino)-2-oxoethyl]pyridine-3-carboxamide | 1338816-01-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-cyclohexyl-N-[2-(3,5-difluoroanilino)-2-oxoethyl]pyridine-3-carboxamide
• CAS: 1338816-01-5
• 化学式: C₂₀H₂₁F₂N₃O₂
• 分子量: 373.402
• InChiKey: AENWDQPNVSPTBK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  62.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3,5-二氟苯胺 在 碳酸氢钠 、 三乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 4.17h， 生成 N-cyclohexyl-N-[2-(3,5-difluoroanilino)-2-oxoethyl]pyridine-3-carboxamide
  参考文献：
  名称：

  Acylglycinamides as inhibitors of glycine transporter type 1

  摘要：

  A screening hit was used as the basis for the core structure of a new series of acylglycinamide GlyT-1 inhibitors. Investigation of the SAR around four areas of diversity used facile chemistry to prepare compounds quickly. By focussing on reducing the lipophilicity and improving the aqueous solubility in the series we were able to prepare a compound (17e) with a good level of activity at GlyT-1, selectivity over GlyT-2 and moderate oral bioavailability. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.07.096

文献信息

• Acylglycinamides as inhibitors of glycine transporter type 1
  作者：Richard Blunt、Roderick Porter、Amanda Johns、David Nash、Gemma Puckey、Paul Wyman、Hugh Herdon、Simon Teague、Victoria Hadden、Stefano Fontana、Laurie Gordon

  DOI：10.1016/j.bmcl.2011.07.096

  日期：2011.10

  A screening hit was used as the basis for the core structure of a new series of acylglycinamide GlyT-1 inhibitors. Investigation of the SAR around four areas of diversity used facile chemistry to prepare compounds quickly. By focussing on reducing the lipophilicity and improving the aqueous solubility in the series we were able to prepare a compound (17e) with a good level of activity at GlyT-1, selectivity over GlyT-2 and moderate oral bioavailability. (C) 2011 Elsevier Ltd. All rights reserved.